Related Experiment Video
Updated: Jul 16, 2026

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Drug-associated acute pancreatitis in paediatric versus adult reports: a disproportionality analysis using FAERS
Annelien Vantrappen1, Nadir Yalcin2, Karen van Hoeve3,4
1Faculty of Medicine, KU Leuven, Leuven, Belgium. annelien.vantrappen@student.kuleuven.be.
Insights
Drug-induced acute pancreatitis is more common in children, with oncology and immunomodulatory drugs frequently implicated. Pharmacovigilance data reveal distinct age-related patterns, necessitating pediatric-specific safety assessments.
Area of Science:
- Pharmacovigilance and Drug Safety
- Pediatric Pharmacology
- Gastroenterology
Background:
- Drug-associated acute pancreatitis (AP) is proportionally more common in children than adults.
- Existing pharmacovigilance data often lack age-specific stratification, limiting recognition and safety assessments in pediatric populations.
- The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) provides a valuable resource for analyzing age-dependent drug safety patterns.
Purpose of the Study:
- To identify drugs associated with acute pancreatitis in children compared to adults.
- To explore age-related differences in drug-induced pancreatitis patterns.
- To improve the recognition and safety of drug-associated pancreatitis in pediatric patients.
Main Methods:
- Retrospective disproportionality analysis of 29,349 reports from the FAERS database (November 1970-February 2026).
- Inclusion of 2,138 pediatric cases (0-17 years).
- Comparison of reporting patterns between pediatric and adult age groups using chi-squared tests, reporting odds ratio (ROR), proportional reporting ratio (PRR), and multivariate regression analysis.
Main Results:
- The top ten suspected drugs in children included methotrexate, pegaspargase, asparaginase, dexamethasone, acetaminophen, prednisone, vincristine sulphate, cytarabine, valproic acid, and mercaptopurine, primarily linked to oncologic and immunomodulatory treatments.
- Adult reports were mainly associated with antidiabetic and cardiovascular agents.
- Seven drugs (dexamethasone, acetaminophen, prednisone, tacrolimus, lamivudine, didanosine, furosemide) showed significantly higher reporting proportions in children (p < 0.01).
- Dexamethasone, tacrolimus, and didanosine demonstrated positive interactions with serious outcomes in adjusted models.
- Serious outcomes and consumer reporting were more frequent in neonates and infants.
Conclusions:
- Distinct age-dependent patterns of drug-associated acute pancreatitis were identified.
- Findings underscore the need for pediatric-specific pharmacovigilance and caution against extrapolating adult reporting patterns to children.
- A clinically relevant list of drugs with high reporting frequencies for acute pancreatitis in children has been generated.
Abstract:
While drug-associated acute pancreatitis is proportionally more prevalent in children than adults, age-stratified pharmacovigilance data remain limited. This study analysed paediatric-specific signals to improve recognition and safety. This study aimed to identify drugs associated with acute pancreatitis in children compared with adults and explored age-related differences in patterns using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). A retrospective disproportionality analysis was conducted on 29,349 reports (November 1970-February 2026) from the FAERS. The dataset included 2138 (7.3%) paediatric cases (0-17 years). Suspected active pharmaceutical ingredients (APIs) were identified, and reporting patterns were compared between age groups (chi-squared, reporting odds ratio (ROR), proportional reporting ratio (PRR), multivariate regression analysis). The top ten suspected drugs in children were as follows: methotrexate, pegaspargase, asparaginase, dexamethasone, acetaminophen, prednisone, vincristine sulphate, cytarabine, valproic acid, and mercaptopurine. Paediatric cases were primarily linked to oncologic and immunomodulatory treatments, whereas adult reports were mainly linked to antidiabetic and cardiovascular agents. Seven APIs present in the top 25 list of children and adults (dexamethasone, acetaminophen, prednisone, tacrolimus, lamivudine, didanosine, furosemide) showed significantly higher reporting proportions in children (p < 0.01). Dexamethasone, tacrolimus, and didanosine showed positive interaction terms with serious outcomes in adjusted models. Serious outcome and consumer-reporting were more common in neonates and infants.
Conclusion:
Distinct age-dependent patterns were identified. These findings support paediatric-specific pharmacovigilance assessment and caution against direct extrapolation of adult spontaneous-reporting patterns to children. A clinically useful list of drugs with the highest reporting frequencies in children has been generated.
What Is Known:
• Drug-associated acute pancreatitis is proportionally more prevalent in children. • The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) can be used to analyse and explore age-dependent patterns.
What Is New:
• The top ten suspected drugs in children were as follows: methotrexate, pegaspargase, asparaginase, dexamethasone, acetaminophen, prednisone, vincristine sulphate, cytarabine, valproic acid, and mercaptopurine, linked to oncology and immunomodulation. • Compared to adults, seven drugs (dexamethasone, acetaminophen, prednisone, tacrolimus, lamivudine, didanosine, furosemide) showed significantly higher reporting proportions in children. Dexamethasone, tacrolimus, and didanosine were associated with serious events.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Acute Pancreatitis I: Introduction
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Pharmacokinetics in Pediatric Patients: Drug Distribution
Chronic Pancreatitis II: Collaborative Care
Assessment:
